Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd..
Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations. Suprabasin (SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed that SBSN is expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression of SBSN was present in a patient group with poor prognosis. SBSN levels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count. In vitro treatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) induced SBSN expression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression of SBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Molecular oncology - 14(2020), 10 vom: 02. Okt., Seite 2403-2419 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pribyl, Miroslav [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.09.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/1878-0261.12768 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312727364 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312727364 | ||
| 003 | DE-627 | ||
| 005 | 20231225145033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/1878-0261.12768 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1042.xml |
| 035 | |a (DE-627)NLM312727364 | ||
| 035 | |a (NLM)32696549 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pribyl, Miroslav |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.09.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. | ||
| 520 | |a Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations. Suprabasin (SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed that SBSN is expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression of SBSN was present in a patient group with poor prognosis. SBSN levels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count. In vitro treatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) induced SBSN expression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression of SBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5-azacytidine | |
| 650 | 4 | |a MDS | |
| 650 | 4 | |a MDSCs | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a suprabasin | |
| 650 | 7 | |a Antigens, Differentiation |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Chemokine CCL2 |2 NLM | |
| 650 | 7 | |a MAS1 protein, human |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Mas |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a SBSN protein, human |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 700 | 1 | |a Hubackova, Sona |e verfasserin |4 aut | |
| 700 | 1 | |a Moudra, Alena |e verfasserin |4 aut | |
| 700 | 1 | |a Vancurova, Marketa |e verfasserin |4 aut | |
| 700 | 1 | |a Polackova, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Stopka, Tomas |e verfasserin |4 aut | |
| 700 | 1 | |a Jonasova, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Bokorova, Radka |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Ota |e verfasserin |4 aut | |
| 700 | 1 | |a Stritesky, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Salovska, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Bartek, Jiri |e verfasserin |4 aut | |
| 700 | 1 | |a Hodny, Zdenek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular oncology |d 2007 |g 14(2020), 10 vom: 02. Okt., Seite 2403-2419 |w (DE-627)NLM179225243 |x 1878-0261 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:10 |g day:02 |g month:10 |g pages:2403-2419 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/1878-0261.12768 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 10 |b 02 |c 10 |h 2403-2419 | ||